Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model
AP Cotrim, AL Sowers, BM Lodde, JM Vitolo… - Clinical cancer …, 2005 - AACR
AP Cotrim, AL Sowers, BM Lodde, JM Vitolo, A Kingman, A Russo, JB Mitchell, BJ Baum
Clinical cancer research, 2005•AACRPurpose: Radiotherapy is commonly used to treat the majority of patients with head and
neck cancers. Salivary glands in the radiation field are dramatically affected by this
procedure. The purpose of this study was to examine pharmacokinetic characteristics of the
stable nitroxide 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine-N-oxyl (tempol) with respect to
radioprotection of the salivary glands. Experimental Design: To evaluate the effect of
different doses and times of administration, the heads of C3H mice were exposed to a single …
neck cancers. Salivary glands in the radiation field are dramatically affected by this
procedure. The purpose of this study was to examine pharmacokinetic characteristics of the
stable nitroxide 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine-N-oxyl (tempol) with respect to
radioprotection of the salivary glands. Experimental Design: To evaluate the effect of
different doses and times of administration, the heads of C3H mice were exposed to a single …
Abstract
Purpose: Radiotherapy is commonly used to treat the majority of patients with head and neck cancers. Salivary glands in the radiation field are dramatically affected by this procedure. The purpose of this study was to examine pharmacokinetic characteristics of the stable nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (tempol) with respect to radioprotection of the salivary glands.
Experimental Design: To evaluate the effect of different doses and times of administration, the heads of C3H mice were exposed to a single irradiation dose of 15 Gy, with i.p. tempol injection. To analyze other routes of administration, we injected 275 mg/kg tempol by an i.m., i.v., or s.c. route, 10 minutes before irradiation. We also tested whether oral administration of tempol in a topical form (either in a mouthwash or gel) provided any salivary gland protection.
Results: Tempol treatment (137.5 or 275 mg/kg, i.p., 10 minutes before irradiation) significantly reduced irradiation-induced salivary hypofunction (∼50-60%). I.v. or s.c. administration of tempol also showed significant radioprotection, whereas i.m. administration proved to be ineffective. Topical use of tempol, either as a mouthwash or gel, also was radioprotective.
Conclusions: Our results strongly suggest that tempol is a promising candidate for clinical application to protect salivary glands in patients undergoing radiotherapy for head and neck cancers.
AACR
